Mapping Neoantigens in Cancer with Genocea’s ATLAS: What to Include, and What to Avoid in Your Cancer Therapy

In oncology, the field of neoantigen prediction is rife with proprietary mathematics for homing in on the best antigens for T cell activation. Only one neoantigen platform, ATLAS, from Genocea, tells you not only about what activates, but also what antigens/epitopes suppress that T cell activity – so called, “inhibigens”. With his platform recently validated in Cancer Discovery, Chip Clark, CEO of Genocea, explains the investment opportunity that is ATLAS.